Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| Serono-001 | Other Identifier | protocol |
Not provided
Not provided
Not provided
poor enrollment
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This protocol will assess the cardiovascular risk associated with growth hormone deficiency in adults. We will use multiple modalities to assess risk for heart attacks or strokes including blood work, ultrasound, MRI and endothelial cell biopsies in both patients who are growth hormone deficient and in patients with normal growth hormone secretion. We hypothesize that adults with growth hormone deficiency will have results suggestive of an increased risk for cardiovascular disease.
Subjects will first be tested for possible growth hormone deficiency. This will be done by administering two intravenous medications that should stimulate growth hormone secretion and we will measure growth hormone in the blood every 30 minutes following the administration. Once we have the results on enough subjects we will split the cohort into those subjects who are growth hormone deficient and those who have normal growth hormone. The two groups will each undergo various tests all designed to assess some component of cardiovascular risk. Ultimately we will compare the results of each test to see if those who are growth hormone deficient have an increased risk for cardiovascular disease.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| A - Normal growth hormone secretion | Active Comparator | Patients who have undergone transsphenoidal surgery for a pituitary adenoma and have normal growth hormone secretion: Subjects will undergo a clinical exam with vital signs and blood draws, anthropometric measurements and skin fold thickness assessments. Subjects will also undergo GH stimulation testing with growth hormone releasing hormone (GHRH) & arginine, MRI and MR spectroscopy, carotid ultrasound, and have an endothelial cell biopsy. |
|
| B - Growth hormone deficient | Active Comparator | Patients who have undergone transsphenoidal surgery for pituitary adenoma who are growth hormone deficient: Subjects will undergo a clinical exam with vital signs and blood draws, anthropometric measurements and skin fold thickness assessments. Subjects will also undergo GH stimulation testing with growth hormone releasing hormone (GHRH) & arginine, MRI and MR spectroscopy, carotid ultrasound, and have an endothelial cell biopsy. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Blood draws | Procedure | Subjects will have serum cardiovascular markers assessed |
|
| Measure | Description | Time Frame |
|---|---|---|
| C-reactive Protein (CRP) Levels | C-reactive protein (CRP) levels in GH sufficient and GH deficient participants | Day 1 |
| Homocysteine Level | Homocytsteine levels in GH sufficient and GH deficient participants | Day 1 |
| Total Cholesterol Level | Total cholesterol levels in GH sufficient and GH deficient participants | Day 1 |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Fat Measured by DXA DEXA | Percentage of total body fat and trunk fat as measured by DXA | Day 1 |
| Lean Body Mass by DXA DEXA | Lean body mass as measured by DXA |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| John C Ausiello, MD | Columbia University | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Columbia University, College of Physicians and Surgeons | New York | New York | 10032 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Growth Hormone (GH) Sufficient Participants | Participants with normal growth hormone secretion. |
| FG001 | Growth Hormone (GH) Deficient Participants | Participants with growth hormone secretion deficiency |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | GH Sufficient Participants | Participants with normal growth hormone secretion. |
| BG001 | GH Deficient Participants | Participants with growth hormone secretion deficiency. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | C-reactive Protein (CRP) Levels | C-reactive protein (CRP) levels in GH sufficient and GH deficient participants | Study was terminated early due to insufficient enrollment and lack of GHRH study medication to be administered. The medication became unavailable in the US after enrollment began, but before that testing could be performed. Without that testing, further classification of subjects as sufficient or deficient could not be performed and the remainder of the tests could not be done. Partial testing was only done on 3 GH deficient subjects and the results of this are reported. | Posted | Mean | Standard Deviation | ng/dL | Day 1 |
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | GH Sufficient Participants | Participants with a history of pituitary disease, but who have a history of being GH sufficient. |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Pamela Freda, MD | Columbia University | 212-305-3725 | puf1@columbia.edu |
Not provided
| ID | Term |
|---|---|
| D004393 | Dwarfism, Pituitary |
| ID | Term |
|---|---|
| D004392 | Dwarfism |
| D001848 | Bone Diseases, Developmental |
| D001847 | Bone Diseases |
| D009140 | Musculoskeletal Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D001800 | Blood Specimen Collection |
| D013007 | Growth Hormone-Releasing Hormone |
| D001120 | Arginine |
| ID | Term |
|---|---|
| D013048 | Specimen Handling |
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| growth hormone releasing hormone (GHRH) & arginine | Drug | Subjects will receive GHRH and arginine intravenously and then have blood drawn at frequent intervals over a 90 minutes to assess growth hormone secretion. |
|
| Carotid ultrasound | Procedure | Subjects will have an ultrasound of their neck to assess their carotid arteries to look for intima-medial thickness. |
|
| MRI | Procedure | Subjects will have MRI and MR spectroscopy of the abdomen and lower extremities to assess for fat in internal organs and muscle. |
|
| Endothelial cell biopsy | Procedure | Subjects will undergo endothelial cell biopsies to harvest endothelial cells to study. It will occur once and takes approximately 20 minutes. Patients will have an iv placed and then a sterile wire is passed back and forth in the iv a couple of times. Three wires are passed. |
|
| Day 1 |
| Insulin Sensitivity as Assessed by Fasting Insulin Levels | Insulin sensitivity as assessed by fasting insulin levels | Day 1 |
| Glucose Levels as Assessed by an Oral Glucose Tolerance Test | Glucose levels as assessed by an oral glucose tolerance test | Day 1 |
| Endothelial Function as Assessed by Flow Mediated Dilatation and Endothelial Cell Biopsy | Endothelial function as assessed by flow mediated dilatation and endothelial cell biopsy for measurement of inflammatory markers. | Day 1 |
| Carotid Intimal-medial Thickness Studies as Assessed by Ultrasound | Carotid intimal-medial thickness studies will be measured by ultrasound | Year 1 |
| Intramyocellular Lipid Content Using MRI and MR Spectroscopy | Intramyocellular lipid content using MRI and MR spectroscopy of the soleus muscle was performed. | Day 1 |
| Intrahepatic Lipid Content Using MRI and MR Spectroscopy | Intrahepatic lipid (IHL) content using MRI and MR spectroscopy of the liver was performed. | Day 1 |
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
Participants with growth hormone secretion deficiency |
|
|
| Primary | Homocysteine Level | Homocytsteine levels in GH sufficient and GH deficient participants | Study was terminated early due to insufficient enrollment and lack of GHRH study medication to be administered. The medication became unavailable in the US after enrollment began, but before that testing could be performed. Without that testing, further classification of subjects as sufficient or deficient could not be performed and the remainder of the tests could not be done. Partial testing was only done on 3 GH deficient subjects and the results of this are reported. | Posted | Mean | Standard Deviation | micromol/L | Day 1 |
|
|
|
| Primary | Total Cholesterol Level | Total cholesterol levels in GH sufficient and GH deficient participants | Study was terminated early due to insufficient enrollment and lack of GHRH study medication to be administered. The medication became unavailable in the US after enrollment began, but before that testing could be performed. Without that testing, further classification of subjects as sufficient or deficient could not be performed and the remainder of the tests could not be done. Partial testing was only done on 3 GH deficient subjects and the results of this are reported. | Posted | Mean | Standard Deviation | mg/dL | Day 1 |
|
|
|
| Secondary | Percentage of Fat Measured by DXA DEXA | Percentage of total body fat and trunk fat as measured by DXA | Study was terminated early due to insufficient enrollment and lack of GHRH study medication to be administered. The medication became unavailable in the US after enrollment began, but before that testing could be performed. Without that testing, further classification of subjects as sufficient or deficient could not be performed and the remainder of the tests could not be done. Partial testing was only done on 3 GH deficient subjects and the results of this are reported. | Posted | Mean | Standard Error | Percent | Day 1 |
|
|
|
| Secondary | Lean Body Mass by DXA DEXA | Lean body mass as measured by DXA | Study was terminated early due to insufficient enrollment and lack of GHRH study medication to be administered. The medication became unavailable in the US after enrollment began, but before that testing could be performed. Without that testing, further classification of subjects as sufficient or deficient could not be performed and the remainder of the tests could not be done. Partial testing was only done on 3 GH deficient subjects and the results of this are reported. | Posted | Mean | Standard Error | kg | Day 1 |
|
|
|
| Secondary | Insulin Sensitivity as Assessed by Fasting Insulin Levels | Insulin sensitivity as assessed by fasting insulin levels | Study was terminated early due to insufficient enrollment and lack of GHRH study medication to be administered. The medication became unavailable in the US after enrollment began, but before that testing could be performed. Without that testing, further classification of subjects as sufficient or deficient could not be performed and the remainder of the tests could not be done. Partial testing was only done on 3 GH deficient subjects and the results of this are reported. | Posted | Mean | Standard Deviation | mIU/L | Day 1 |
|
|
|
| Secondary | Glucose Levels as Assessed by an Oral Glucose Tolerance Test | Glucose levels as assessed by an oral glucose tolerance test | Study was terminated early due to insufficient enrollment and lack of GHRH study medication to be administered. The medication became unavailable in the US after enrollment began, but before that testing could be performed. Without that testing, further classification of subjects as sufficient or deficient could not be performed and the remainder of the tests could not be done. Partial testing was only done on 3 GH deficient subjects and the results of this are reported. | Posted | Mean | Standard Deviation | mg/dL | Day 1 |
|
|
|
| Secondary | Endothelial Function as Assessed by Flow Mediated Dilatation and Endothelial Cell Biopsy | Endothelial function as assessed by flow mediated dilatation and endothelial cell biopsy for measurement of inflammatory markers. | Study was terminated early due to insufficient enrollment and lack of GHRH study medication to be administered. The medication became unavailable in the US after enrollment began, but before that testing could be performed. Without that testing, further classification of participants as sufficient or deficient could not be performed and the remainder of the tests could not be done. As a result, data were not collected for GH sufficient or GH deficient participants for this outcome measure | Posted | Day 1 |
|
|
| Secondary | Carotid Intimal-medial Thickness Studies as Assessed by Ultrasound | Carotid intimal-medial thickness studies will be measured by ultrasound | Study was terminated early due to insufficient enrollment and lack of GHRH study medication to be administered. The medication became unavailable in the US after enrollment began, but before that testing could be performed. Without that testing, further classification of participants as sufficient or deficient could not be performed and the remainder of the tests could not be done. As a result, data were not collected for GH sufficient and GH deficient participants. | Posted | Year 1 |
|
|
| Secondary | Intramyocellular Lipid Content Using MRI and MR Spectroscopy | Intramyocellular lipid content using MRI and MR spectroscopy of the soleus muscle was performed. | Study was terminated early due to insufficient enrollment and lack of GHRH study medication to be administered. The medication became unavailable in the US after enrollment began, but before that testing could be performed. Without that testing, further classification of subjects as sufficient or deficient could not be performed and the remainder of the tests could not be done. Partial testing was only done on 3 GH deficient subjects and the results of this are reported. | Posted | Mean | Standard Deviation | Percent water signal | Day 1 |
|
|
|
| Secondary | Intrahepatic Lipid Content Using MRI and MR Spectroscopy | Intrahepatic lipid (IHL) content using MRI and MR spectroscopy of the liver was performed. | Study was terminated early due to insufficient enrollment and lack of GHRH study medication to be administered. The medication became unavailable in the US after enrollment began, but before that testing could be performed. Without that testing, further classification of subjects as sufficient or deficient could not be performed and the remainder of the tests could not be done. Partial testing was only done on 3 GH deficient subjects and the results of this are reported. | Posted | Mean | Standard Deviation | Percent water signal | Day 1 |
|
|
|
| 0 |
| 4 |
| 0 |
| 4 |
| 0 |
| 4 |
| EG001 | GH Deficient Participants | Participants with a history of pituitary disease who have a history of being GH deficient | 0 | 3 | 0 | 3 | 0 | 3 |
Not provided
Not provided
Not provided
| D001849 |
| Bone Diseases, Endocrine |
| D007018 | Hypopituitarism |
| D010900 | Pituitary Diseases |
| D007027 | Hypothalamic Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D004700 | Endocrine System Diseases |
| D011677 | Punctures |
| D013514 | Surgical Procedures, Operative |
| D008919 | Investigative Techniques |
| D010906 | Pituitary Hormone-Releasing Hormones |
| D007028 | Hypothalamic Hormones |
| D036361 | Peptide Hormones |
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |
| D009479 | Neuropeptides |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
| D009419 | Nerve Tissue Proteins |
| D011506 | Proteins |
| D024361 | Amino Acids, Basic |
| D000596 | Amino Acids |
| D000599 | Amino Acids, Diamino |
| D000601 | Amino Acids, Essential |